Briefing
Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.
At a median follow-up of 7.0 months, 3 of 22 patients (14%) were ctDNA-positive at any timepoint (all <100 ppm); 2 of those 3 developed radiographic recurrence. Only 1 of 20 patients negative at the 3-month landmark recurred, and 0 of 16 with persistent ctDNA negativity recurred during follow-up.
- n: 22 patients, 42 plasma samples; single-center retrospective
- Assay: Next Personal Dx whole-genome tumor-informed assay (Personalis)